Metformin as a Longevity Drug: What TAME Is Trying to Prove
Metformin is the most-prescribed diabetes drug in the world. Longevity researchers think it may have anti-aging effects beyond glucose control. Here's the evidence and the ongoing trial.
Metformin has been used for type 2 diabetes since the 1950s. It's safe, cheap, off-patent, and in the last decade has become the subject of serious longevity research.
The hypothesis: metformin's effects on AMPK activation, mTOR suppression, and mitochondrial function may have anti-aging effects independent of glucose control.
The observational data
Multiple large observational studies have found that diabetic patients on metformin have lower rates of cancer, cardiovascular disease, and all-cause mortality compared to diabetics on other medications — and in some analyses, compared to non-diabetic controls not on metformin.
A 2014 study by Bannister et al. found metformin-treated diabetics had lower mortality than matched non-diabetic controls. This is remarkable because diabetics should have worse outcomes — suggesting metformin was providing a mortality benefit that exceeded the diabetes penalty.
These are observational studies with confounders, but the consistency across datasets is notable.
The mechanism
Metformin's primary mechanism is inhibiting complex I of the mitochondrial electron transport chain, reducing hepatic glucose production. But it also:
- Activates AMPK (the cellular energy sensor and mTOR inhibitor)
- Suppresses mTORC1 (the longevity pathway also targeted by rapamycin)
- Reduces circulating IGF-1
- Has anti-inflammatory properties
The AMPK/mTOR pathway overlap with rapamycin's mechanism is why metformin and rapamycin are often co-prescribed in longevity protocols — they hit overlapping but complementary targets.
The TAME trial
TAME (Targeting Aging with Metformin) is a $75 million randomized controlled trial currently underway, funded by the American Federation for Aging Research. It's the first clinical trial designed to test a drug against aging itself — with all-cause mortality and age-related disease incidence as endpoints.
If TAME shows benefit, metformin would be the first drug with RCT evidence for aging as a primary endpoint. Results are expected in the late 2020s.
Current practice
While TAME is ongoing, many longevity physicians are prescribing metformin to non-diabetic patients based on the observational evidence and favorable safety profile. The typical longevity dose is 500–1000mg once or twice daily — lower than the 2000–2500mg doses used for diabetes.
The main side effect is GI upset (nausea, diarrhea), which is common and usually resolves. Extended-release formulations reduce this. Metformin depletes B12 over time — your physician will monitor this.